TNFRSF11B and bone cancer: During the process of bone cancer pain, aberrant activation of osteoclasts and compensatively increased osteoblast activity contribute to the bone structural damage and are positively regulated by the receptor activator of nuclear factor-κB (RANK) ligand (RANKL) [12], but negatively regulated by osteoprotegerin (OPG).